Phase I: Determine the Recommended dose (RD) 10 weeks [clinicaltrials_resource:2b830425f9a37c34dbfed377dc2bdb53]

Phase I: Determine the Recommended dose (RD) 10 weeks [clinicaltrials_resource:2b830425f9a37c34dbfed377dc2bdb53]

Based on the incidence of dose-limited toxicities(DLT), the RD is determined from 4 test levels
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:2b830425f9a37c34dbfed377dc2bdb53
Preoperative S-1/OHP With Radiation Therapy for Low-lying Rectal Carcinoma in Neo-adjuvant Setting [clinicaltrials:NCT01227239]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Phase I: Determine the Recommended dose (RD) 10 weeks [clinicaltrials_resource:2b830425f9a37c34dbfed377dc2bdb53]

Based on the incidence of dose-limited toxicities(DLT), the RD is determined from 4 test levels
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:2b830425f9a37c34dbfed377dc2bdb53
Bio2RDF identifier
2b830425f9a37c34dbfed377dc2bdb53
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:2b830425f9a37c34dbfed377dc2bdb53
measure [clinicaltrials_vocabulary:measure]
Phase I: Determine the Recommended dose (RD)
time frame [clinicaltrials_vocabulary:time-frame]
description
Based on the incidence of dose ...... determined from 4 test levels
identifier
clinicaltrials_resource:2b830425f9a37c34dbfed377dc2bdb53
title
Phase I: Determine the Recommended dose (RD) 10 weeks
@en
inDataset
type
label
Phase I: Determine the Recomme ...... 30425f9a37c34dbfed377dc2bdb53]
@en